BRPI0414059A - sìntese seletiva de pirimidinas substituìdas em cf3 - Google Patents

sìntese seletiva de pirimidinas substituìdas em cf3

Info

Publication number
BRPI0414059A
BRPI0414059A BRPI0414059-1A BRPI0414059A BRPI0414059A BR PI0414059 A BRPI0414059 A BR PI0414059A BR PI0414059 A BRPI0414059 A BR PI0414059A BR PI0414059 A BRPI0414059 A BR PI0414059A
Authority
BR
Brazil
Prior art keywords
formula
selective synthesis
compound
substituted pyrimidines
substituted
Prior art date
Application number
BRPI0414059-1A
Other languages
English (en)
Inventor
John Charles Kath
Daniel Tyler Richter
Michael Joseph Luzzio
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0414059A publication Critical patent/BRPI0414059A/pt
Publication of BRPI0414059B1 publication Critical patent/BRPI0414059B1/pt
Publication of BRPI0414059B8 publication Critical patent/BRPI0414059B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)

Abstract

"SìNTESE SELETIVA DE PIRIMIDINAS SUBSTITUìDAS EM CF3". A presente invenção refere-se com um método de preparar um composto de fórmula (I) em que X¬ 1¬, X¬ 2¬ e R¬ 3¬ -R¬ 4¬ são como aqui definido. O método inclui reagir um composto de fórmula (II) com uma amina de fórmula (III) (HNR¬ 3¬R¬ 4¬) na presença de um ácido de Lewis e uma base não-nucleófila. A porção 2,4-diaminopirimidina é um componente comum em várias moléculas semelhantes a fármaco biologicamente ativas e verificou-se que derivados de pirimidina são úteis no tratamento de crescimento celular anormal, tal como câncer, em mamíferos.
BRPI0414059A 2003-09-05 2004-08-24 síntese seletiva de pirimidinas substituídas em cf3 BRPI0414059B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50073303P 2003-09-05 2003-09-05
PCT/IB2004/002744 WO2005023780A1 (en) 2003-09-05 2004-08-24 Selective synthesis of cf3-substituted pyrimidines

Publications (3)

Publication Number Publication Date
BRPI0414059A true BRPI0414059A (pt) 2006-10-24
BRPI0414059B1 BRPI0414059B1 (pt) 2018-11-06
BRPI0414059B8 BRPI0414059B8 (pt) 2021-05-25

Family

ID=34272990

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414059A BRPI0414059B8 (pt) 2003-09-05 2004-08-24 síntese seletiva de pirimidinas substituídas em cf3

Country Status (24)

Country Link
US (1) US7122670B2 (pt)
EP (1) EP1663991B1 (pt)
JP (1) JP4842816B2 (pt)
KR (1) KR100694732B1 (pt)
CN (1) CN100465164C (pt)
AR (1) AR045557A1 (pt)
BR (1) BRPI0414059B8 (pt)
CA (1) CA2537373C (pt)
CO (1) CO5650237A2 (pt)
CY (1) CY1106370T1 (pt)
DE (1) DE602004004287T2 (pt)
DK (1) DK1663991T3 (pt)
ES (1) ES2276344T3 (pt)
HK (1) HK1091824A1 (pt)
IL (1) IL173363A (pt)
MX (1) MXPA06002552A (pt)
NO (1) NO334383B1 (pt)
NZ (1) NZ544969A (pt)
PL (1) PL1663991T3 (pt)
PT (1) PT1663991E (pt)
RU (1) RU2315759C2 (pt)
TW (1) TWI283667B (pt)
WO (1) WO2005023780A1 (pt)
ZA (1) ZA200600747B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2529611C (en) * 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
JP4778717B2 (ja) * 2005-03-25 2011-09-21 富士フイルム株式会社 複素環式化合物の製造方法
DE102007010801A1 (de) 2007-03-02 2008-09-04 Bayer Cropscience Ag Diaminopyrimidine als Fungizide
ES2593486T3 (es) * 2007-04-18 2016-12-09 Pfizer Products Inc. Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
US8372974B2 (en) 2008-03-20 2013-02-12 Boehringer Ingelheim International Gmbh Regioselective preparation of substituted pyrimidines
UY31714A (es) 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
DE102009006643A1 (de) * 2009-01-29 2010-08-05 Saltigo Gmbh Herstellung von halogenierten N-heteroaromatischen Polyhalogenderivaten
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
US8933227B2 (en) * 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US9133224B2 (en) 2010-11-29 2015-09-15 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
UY33817A (es) 2010-12-21 2012-07-31 Boehringer Ingelheim Int ?nuevas oxindolpirimidinas bencílicas?.
EP2675794B1 (en) 2011-02-17 2019-02-13 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
EP2675793B1 (en) 2011-02-17 2018-08-08 Cancer Therapeutics Crc Pty Limited Fak inhibitors
WO2014126954A1 (en) 2013-02-13 2014-08-21 OSI Pharmaceuticals, LLC Regioselective synthesis of substituted pyrimidines
WO2015170600A1 (ja) 2014-05-08 2015-11-12 東ソー・エフテック株式会社 ５－（トリフルオロメチル）ピリミジン誘導体及びその製造方法
JP6391985B2 (ja) * 2014-05-16 2018-09-19 東ソー・ファインケム株式会社 ２−置換−４−（２，２，２−トリフルオロエトキシ）−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
JP6391988B2 (ja) * 2014-05-21 2018-09-19 東ソー・ファインケム株式会社 ５−（トリフルオロメチル）ピリミジン誘導体の製造方法及び新規５−（トリフルオロメチル）ピリミジン誘導体
CN108440499A (zh) * 2018-03-22 2018-08-24 盐城师范学院 一种色瑞替尼及其关键中间体的制备方法
CN114213339B (zh) * 2021-12-20 2023-10-31 苏州康纯医药科技有限公司 一种表皮细胞生长因子受体突变抑制剂的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
CA2463989C (en) * 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof

Also Published As

Publication number Publication date
AR045557A1 (es) 2005-11-02
IL173363A0 (en) 2006-06-11
US7122670B2 (en) 2006-10-17
MXPA06002552A (es) 2006-06-20
DK1663991T3 (da) 2007-04-10
DE602004004287T2 (de) 2007-06-21
RU2006106727A (ru) 2006-06-27
CA2537373C (en) 2009-10-20
RU2315759C2 (ru) 2008-01-27
NZ544969A (en) 2008-07-31
WO2005023780A1 (en) 2005-03-17
AU2004270480A1 (en) 2005-03-17
NO20061509L (no) 2006-04-03
BRPI0414059B1 (pt) 2018-11-06
BRPI0414059B8 (pt) 2021-05-25
CY1106370T1 (el) 2011-10-12
US20050101620A1 (en) 2005-05-12
EP1663991A1 (en) 2006-06-07
HK1091824A1 (en) 2007-01-26
JP4842816B2 (ja) 2011-12-21
ES2276344T3 (es) 2007-06-16
PL1663991T3 (pl) 2007-04-30
KR100694732B1 (ko) 2007-03-14
JP2007504211A (ja) 2007-03-01
CO5650237A2 (es) 2006-06-30
KR20060030918A (ko) 2006-04-11
IL173363A (en) 2010-05-31
DE602004004287D1 (de) 2007-02-22
CN1845906A (zh) 2006-10-11
EP1663991B1 (en) 2007-01-10
TWI283667B (en) 2007-07-11
CN100465164C (zh) 2009-03-04
ZA200600747B (en) 2007-03-28
NO334383B1 (no) 2014-02-24
TW200514773A (en) 2005-05-01
PT1663991E (pt) 2007-02-28
CA2537373A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
BRPI0414059A (pt) sìntese seletiva de pirimidinas substituìdas em cf3
BRPI0417052A (pt) processo para a preparação de compostos
TNSN06074A1 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
TW200740805A (en) Novel compounds
NZ596025A (en) [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
BR0313396A (pt) 3-pirrolil-piridopirazóis e 3-pirrolil-indazóis, como inibidores de quinase
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
NO20082338L (no) Pyrimidinderivater for behandling av avvikende cellevekst
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
BRPI0415855A (pt) processo para preparação de ésteres de ácido 2-dihalogenacil-3-amino-acrìlico e ésteres de ácido 3-dihalogeno-metil-pirazol-4-carboxìlico
EA201070874A1 (ru) Производные индол-2-карбоксамидов и азаиндол-2-карбоксамидов, замещённых силанильной группой, их получение и применение в терапии
BR0316470A (pt) Derivados de 3-amino-piperadina e métodos de preparação
BRPI0416690A (pt) derivados de pirrol
DE602004031115D1 (de) Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga
BRPI0108990B8 (pt) processo para preparação de derivados de pirimidona com atividade antifungos
EA200700767A1 (ru) Способ получения пиразолов
ATE332336T1 (de) Azoverbindungen
ITMI20020933A1 (it) Procedimento per la sintesi di clopidogrel
TW200616624A (en) 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity
DE602006009668D1 (de) 5-pyridinyl-1-azabicycloä3.2.1üoctan-derivate, herstellungsverfahren und deren verwendung für therapeutika
IL183805A0 (en) Process for preparing substituted thiophenesulfonyl isocyanates
EA200870045A1 (ru) СУЛЬФОКСИМИННЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ p38 MAP КИНАЗЫ
BRPI0416377A (pt) processo para a sìntese de imidazóis
DK0504290T3 (da) Inhibitorer af dihydrofylatreduktase fra Pneumocystis carinii

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. C07D 239/42; A61P 35/00

Ipc: C07D 239/42 (2011.01), A61P 35/00 (2011.01)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/08/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF